Abstract
The infection by Human immunodeficiency virus (HIV) has high incidence with 2,7 millions cases reported in 2010. Sensitive distal peripheral neuropathy (SDPN) is the most common nervous system disease caused by HIV infection. This entity characteristically painful could be associated directly to infection: polyneuropathy distal symmetric (PDS) or secondary for antiretroviral agents neurotoxicity: neuropathy toxic antiretroviral (NTA). In order to explain its physiopathology many hypothesis are proposed; the most recent hypothesis accepted suggest a synergy level between NTA and DSP, with mechanisms inflammatory in common. Other mechanisms proposed are mitochondrial dysfunction mediated by mitochondrial polymerase gamma depletion, creatine deficit and direct viral protein toxicity, especially by glycoprotein 120. Future investigations are required for developing new therapeutics targets to manage and treat NSDP.
References
World Health Organization (WHO). Joint United Nations Programme on HIV/ AIDSNAIDS. AIDS epidemic update; WHO Library 2006.
World Health Organization (WHO). Hacia el acceso universal, Expansión de las intervenciones prioritarias contra el VIH/SIDA en el sector de la salud. WHO library 2008.
ELLIS RJ, ROSARIO D, CLIFFORD DB, MCARTHUR JC, SIMPSON D, ALEXANDER T, ET AL. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: The CHARTER Study. Arch Neurol 2010; 67: 552-8.
SCHIFITTO G, MCDERMOTT MP, MCARTHUR JC, MARDER K, SACKTOR N, EPSTEIN L, ET AL. Incidence of and risk factors for HIV associated distal sensory polyneuropathy. Neurology 2002; 58: 1764-8.
SIMPSON DM, KITCH D, EVANS SR, MCARTHUR JC, ASMUTH DM, COHEN B, ET AL. HIV neuropathy natural history cohort study: Assessment measures and risk factors. Neurology 2006; 66: 1679-87.
KESWANI SC, POLLEY M, PARDO CA, GRIFFIN JW, MCARTHUR JC, HOKE A. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003; 54: 287-96.
KESWANI SC, PARDO CA, CHERRY CL, HOKE A, MCARTHUR JC. HIV-associated sensory neuropathies. AIDS 2002; 16:2105-2117.
FERRARI S, VENTO S, MONACO S, CAVALLARO T, CAINELLI F, RIZZUTO N, ET AL. Human immunodeficiency virus associated peripheral neuropathies. Mayo Clin Proc 2006; 81:213-219.
SO YT, HOLTZMAN DM, ABRAMS DI, OLNEY RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome: prevalence and clinical features from a population-based study. Arch Neurol 1988; 45: 945-8.
DE LA MONTE SM, GABUZDA DH, HO DD, BROWN RH JR, HEDLEY-WHYTE ET, SCHOOLEY RT, ET AL. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 1988; 23: 485-92.
VILLELABEITIA-JAUREGUIZAR K, RIVAS-GONZÁLEZ P, IBARRA-LUZAR JI, FERNÁNDEZ-GARCÍA C, GOYENECHEA-HERRERO A, BRAVO-RUEDA AF, ET AL. Neuropatía clínica y subclínica de pacientes con virus de inmunodeficiencia humana en tratamiento antirretroviral. Rev Neurol 2006; 42(9): 513-20.
PETIT F, FROMENTY B, OWEN A, ESTAQUIER J. Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci 2005; 26: 258-64.
WALLACE VCJ, BLACKBEARD J, PHEBY T, SEGERDAHL AR, DAVIES M, HASNIE F, ET AL. Pharmacological, behavioral and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 2007; 133: 47-63.
HULGAN T, HAAS DW, HAINES JL, RITCHIE MD, ROBBINS GK, SHAFER RW. ET AL. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: An adult AIDS clinical trials group study. AIDS 2005; 19: 1341-49.
ARASHO BD, JACOB SB, ZENEBE G. Distal symmetric polyneuropathy and toxic neuropathy in HIV patients. Ann Trop Med Public Health 2010; 3(1): 8-13.
MOYLE G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911-36.
JOSEPH EK, CHEN X, KHASAR SG, LEVINE JD. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 2004; 107 (1-2):147-58.
FUMALARO G, MORETTI S, MARCELLINI S. Acetylcarnitine deficiency in AIDS patients with neurotoxicity on treatment with antiviral nucleoside analogues. AIDS 1997; 11: 185-90.
AKAMBI MO, SCARCI K, TAIWO B, MURPHY RL. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. Expert Opin Pharmacother 2012; 13 (1):65-79.
BOYD SD. Management of HIV infection in treatment- naive patients: a review of the most current recommendations. Am J Healt Syst Pharm 2011; 68(11): 991-1001.
ELLIS R, MARQUIE J. HIV Protease inhibitors and risk of peripheral neuropathy. Ann Neurol 2008; 64(5): 566-72.
JOSEPH EK, LEVINE JD. Mitochondrial electron transport in models of neuropathic and inflammatory pain. Pain 2006; 121: 105-14.
LEE H. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003; 42: 14711-19.
BENBRIK E, CHARRIOT P, BONAVAUD S. AMMI-SAÏD M, FRISDAL E, REY C, ET AL. Cellular and mitochondrial toxicity of zidovudine (AZT) didanosine (ddl) y zalcitabine (ddc) on cultured human muscle cell. J Neurol Sci 1997; 149: 19-25.
GREENSPAN HC, ARUOMA OI. Oxidative stress and apoptosis in HIV infection: a role for plant-derived metabolites with synergistic antioxidant activity. Immunol Today 1995; 15: 209-13.
MACHO A. Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood 1995; 86: 2481-7.
LEHMANN HC, CHEN W, BORZAN J, MANKOWSKI JL, HÖKE A. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann Neurol 2011; 69: 100-10.
RENN C, LEITCH C, LESSANS S. Brain-Derived Neurotrophic Factor modulates antiretroviral-induced mechanical allodynia in the mouse. J Neurosci Res 2011; 89(10): 1551-65.
KESWANI SC, JACK C, ZHOU C, HÖKE A. Establishment of a rodent model of HIV-associated sensory neuropathy. J Neurosci 2006; 4;26(40):10299-304.
BERGER AR, AREZZO JC, SCHAUMBURG HH, SKOWRON G, MERIGAN T, BOZZETTE S, ET AL. 2', 3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993; 43: 358-62.
BHANGOO SK, RIPSCH MS, BUCHANAN DJ, MILLER RJ, WHITE FA. Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain 2009; 5:48.
SCHIFITTO G, MCDERMOTT MP, MCARTHUR JC, MARDER K, SACKTOR N, MCCLERNON DR, ET AL. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005; 64(5):842-8.
Flonen Alli DALAKAS MC. Peripheral neuropathy and retroviral drugs. J Peripher Nerv Syst 2001; 6: 14-20.
ACHARJEE S, NOORBAKHSH F, STEMKOWSKI PL, OLECHOWSKI C, COHEN EA, BALLANYI K, ET AL. HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. FASEB J 2010; 24:4343-4353.
AHMED F, MACARTHUR L, DE BERNARDI MA, MOCCHETTI I. Retrograde and anterograde transport of HIV protein gp120 in the nervous system. Brain Behav Immun 2009; 23:355-364.
KIEBURTZ KD, GIANG DW, SCHIFFER RB, VAKIL N. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection: association with neurological dysfunction. Arch Neurol 1991; 48: 312-4.
CHERRY C, LALA L, WESSELINGH SL. Mitochondrial toxicity of nucleoside analogues: mechanism, monitoring, and management. Sex Health 2005; 2: 1-11.
BANERJEE A, STRAZZA M, WIGDAHL B, PIRRONE V, MEUCCI O, NONNEMACHER MR. Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol 2011; 17: 291-302.
KAMERMAN PR, MOSS PJ, WEBER J, WALLACE VCJ, RICE ASC, WANG W. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J Peripher Nerv Syst 2012; 17(1):19-31.
OCHONISKY S, VERROUST J, BASTUJI-GARIN S, GHERARDI R, REVUZ J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66-9.
WULFF EA, WANG KA, SIMPSON DM. HIV-associated peripheral neuropathy. Epidemiology, pathophysiology and treatment. Drugs 2000; 59: 1251.
GRIFFIN JW, WESSELINGH S, OAKLANDER AL, KUNCL RW, GRIFFIN DE. mRNA fingerprinting of cytokines and growth factors: a new means of characterizing nerve biopsies. Neurology 1993; 43 (4):A232.
PARDO CA, MCARTHUR JC, GRIFIN JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Sys 2001 6(1):21-7.
BALLANTYNE C, COUSINS M, GIAMBERARDINO M. Painful HIV-Associated Sensory Neuropathy. IASP Pain clinical updates 2010; XVIII (3): 2-8.
SMITH S. Treatment Considerations in Painful HIV-Related Neuropathy. Pain Physician 2011; 14: E505-24.
ZHENG W, OUYANG H, ZHENG X, LIU S, MATA M, FINK DJ. ET AL. Glial TNFalpha in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats. Mol Pain 2011; 7:40.
SCHOENIGER-SKINNER DK, LEDEBOER A, FRANK MG, MILLIGAN ED, POOLE S, MARTIN D, ET AL. Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp 120. Brain Behav Immun 2007; 21: 660-7.
WANG SS, SHULTZ JR, BURISH MJ. Functional trade-offs in white matter axonal scaling. J Neurosci 2008; 28: 4047-56.
ROBINSON B, LI Z, NATH A. Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures. J Neurovirol 2007; 13: 160-7.
STYS PK, WAXMAN SG, RANSOM BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Naþ channels and Na(þ)-Ca2þ exchanger. J Neurosci 1992; 12: 430-9.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.